Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
The Baird Chautauqua International Growth Fund Haicheng Li, CFA | “WuXi Biologics' new order momentum remains robust, and its capex plan is progressing as scheduled. The stock had appreciated over 100% in the first three quarters of the year and faced some profit-taking in 4Q25. BSD Analysis: WuXi Biologics is one of the world's most important outsourced biologics manufacturers, sitting deep inside global pharma supply chains. Its scale, technical depth, and integrated services make it extremely sticky for clients developing complex biologics. Geopolitical risk has dominated sentiment, but customer behavior has been far more stable than the stock implies. Demand for biologics manufacturing continues to grow as pipelines get more complex and internal capacity stays constrained. Margins remain attractive despite pricing pressure from large clients. Capital intensity is high, but returns scale with utilization. WuXi is a core life-sciences infrastructure asset trading with a heavy geopolitical discount.” | BULL | Q4 2025 Jan 1, 2026 | View Pitch |
Baillie Gifford -International Growth Thomas Coutts / Brian Lum / Julia Angeles / Lawrence Burns / Robert Wilson | “Wuxi Biologics is highlighted as a top contributor among Chinese holdings that have executed well operationally. It continues to deliver robust performance amidst positive momentum.” | BULL | Q1 2025 Apr 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
